Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/103835
Título: | Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis | Autor: | Pessoa, Bernardete Malheiro, Luísa Carneiro, Inês Monteiro, Sílvia Coelho, João Coelho, Constança Figueira, João Meireles, Angelina Beirão, João Nuno Melo |
Palavras-chave: | aflibercept; bevacizumab; diabetic macular edema; ranibizumab, refractory | Data: | 2021 | Editora: | Dove Medical Press | Título da revista, periódico, livro ou evento: | Clinical Ophthalmology | Volume: | 15 | Resumo: | Aim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab. Methods: Single-center retrospective comparative study of patients with DME unresponsive to intravitreal bevacizumab that was switched to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were analysed prior to and 4 months after the switch. Ocular coherence tomography (OCT) biomarkers were also analysed. Results: Fifty-six eyes from 40 patients were included in the study, 33 eyes switched to ranibizumab and 23 to aflibercept. A significant median CFT decrease was observed in both groups (p<0.001), with no between-group differences. BCVA gain was only significant in the ranibizumab group (p<0.001). None of the pre-baseline or baseline parameters were associated with the response to ranibizumab or aflibercept. Conclusion: In persistent DME unresponsive to bevacizumab, both anatomical and functional improvements were observed with ranibizumab whereas aflibercept only showed an anatomical improvement. Clinicaltrials.gov NCT04018833. | URI: | https://hdl.handle.net/10316/103835 | ISSN: | 1177-5467 | DOI: | 10.2147/OPTH.S280644 | Direitos: | openAccess |
Aparece nas coleções: | FMUC Medicina - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Intravitreal-ranibizumab-or-aflibercept-after-bevacizumab-in-diabetic-macular-edema-Exploratory-retrospective-analysis2021Clinical-OphthalmologyOpen-Access.pdf | 1.81 MB | Adobe PDF | Ver/Abrir |
Visualizações de página
57
Visto em 15/mai/2024
Downloads
47
Visto em 15/mai/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons